Potassium Chloride Extended Release Tablets
ID: SPE2D2-24-R-0013Type: Solicitation
Overview

Buyer

DEPT OF DEFENSEDEFENSE LOGISTICS AGENCYDLA TROOP SUPPORTPHILADELPHIA, PA, 19111, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/ae75b4c1ed3b4b48892acfd42022a071/view
Timeline
    Description

    The Defense Logistics Agency (DLA) is soliciting bids for the procurement of Potassium Chloride Extended Release Tablets under Solicitation No. SPE2D2-24-R-0013. This procurement involves various package sizes of potassium chloride tablets, specifically 10 MEQ and 20 MEQ in both 100 and 500 count bottles, with estimated quantities spanning a base year and four optional additional years. The initiative is crucial for maintaining a reliable supply of essential pharmaceuticals to support healthcare needs within the Department of Defense. Interested suppliers must submit their proposals electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS) by the deadline of October 10, 2024. For further inquiries, potential bidders can contact Ryan Guarnere at ryan.guarnere@dla.mil or Jason Wray at jason.wray@dla.mil.

    Files
    Title
    Posted
    Potassium Chloride SPE2D224R0013 Solicitation-Schedule of Supplies.pdf
    The document pertains to Solicitation No. SPE2D2-24-R-0013, detailing the procurement of Potassium Chloride Extended Release (ER) tablets in various quantities for multiple contract years. It outlines the estimated quantities for four distinct products: 10 MEQ tablets in both 100 and 500 count bottles, and 20 MEQ tablets in similar counts. Each item is specified by its National Drug Code (NDC), and the quantities listed are indicative estimates based on regulatory requirements, specifically referencing FAR 52.216-21 pertaining to requirements. The procurement spans five years, including a base year followed by four option years. The decision to provide these products is essential for fulfilling health-related needs within the jurisdiction of the solicitation, which is typical of government Requests for Proposals (RFPs). Overall, this document serves as an official request for suppliers to deliver specified pharmaceutical supplies efficiently and in compliance with federal guidelines.
    Potassium Chloride SPE2D224R0013 Solicitation-Schedule of Supplies Updated.pdf
    The document outlines Solicitation No. SPE2D2-24-R-0013, focusing on the procurement of Potassium Chloride extended-release tablets in various package sizes under a federal Request for Proposal (RFP). The proposal specifies estimated quantities for four product types, each offered in both 100 and 500 count bottles, across a base year and four optional additional years. The quantities listed are purely estimates, in alignment with Federal Acquisition Regulation (FAR) guidance. The primary purpose is to solicit bids from suppliers for the specified pharmaceutical products, establishing a structured approach for potential contractors detailing the items, estimated amounts, and packaging requirements. The breakdown includes distinct item numbers, unit pricing, and overall quantity estimations per item for effective evaluation and tracking of supplies needed. This RFP is part of the federal government's strategy to maintain and procure essential pharmaceuticals, reflecting broader initiatives to ensure healthcare provision through regulated and transparent procurement processes.
    Potassium Chloride SPE2D224R0013 Solicitation.pdf
    The document is a federal solicitation (SPE2D2-24-R-0009) issued by the Defense Logistics Agency (DLA) for pharmaceuticals, specifically potassium chloride tablet products in various quantities. It outlines submission instructions, including that offers must be submitted electronically through the Defense Logistics Agency Internet Bid Board System (DIBBS) by the deadline of October 10, 2024. Additionally, it includes detailed contract clauses emphasizing compliance with federal acquisition regulations, including subcontracting plans for large businesses and performance assessments for contracts over $250,000. Key contract clauses govern various topics, including contractor ethics, trade agreements, duty-free entry, and telecommunications equipment restrictions. The statement of work further defines the objectives, compliance requirements, and processes for product registration and delivery. This solicitation aims to ensure contracted suppliers meet federal standards for procurement while facilitating compliance and transparency in federal contracting processes.
    SF30_SPE2D224R00130001.PDF
    SF30_SPE2D224R00130002.PDF
    SF30_SPE2D224R00130003.PDF
    SF30_SPE2D224R00130004.PDF
    SF30_SPE2D224R00130005.PDF
    SF30_SPE2D224R00130006.PDF
    SF30_SPE2D224R00130007.PDF
    Lifecycle
    Title
    Type
    Potassium Chloride Extended Release Tablets
    Currently viewing
    Solicitation
    Potassium Chloride Extended Release Tablets
    Presolicitation
    Similar Opportunities
    Bicalutamide 50MG tablets
    Active
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Bicalutamide 50MG tablets, available in bottle counts of 30 and 500. The procurement aims to establish a reliable national supply source for these pharmaceutical products, which are critical for various Department of Defense and other federal health programs. This unrestricted and fully competitive acquisition will be a firm-fixed price contract with a one-year base period and four one-year options, with the solicitation expected to be posted on the DLA Bid Board System and Sam.gov. Interested parties should direct inquiries to Keith Ryales at keith.ryales@dla.mil or call 215-737-9199 for further information.
    Pramipexole Tablets
    Active
    Dept Of Defense
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting proposals for Pramipexole Tablets under solicitation number SPE2D2-24-R-0017. This procurement aims to acquire pharmaceutical products, specifically Pramipexole in various dosages, to support military health needs. The solicitation outlines detailed requirements for offerors, including submission instructions via the Defense Logistics Agency Internet Bid Board System (DIBBS), compliance with federal regulations, and the necessity for performance assessments and ethical conduct. Interested contractors should reach out to Ryan Guarnere at Ryan.Guarnere@dla.mil or Jason Wray at jason.wray@dla.mil for further information regarding the submission process and compliance requirements.
    Lamotrigine
    Active
    Dept Of Defense
    The Defense Logistics Agency (DLA) is preparing to issue a solicitation for a national requirements contract for Lamotrigine ER Tablets, specifically in dosages of 25MG, 50MG, 100MG, 200MG, 250MG, and 300MG, packaged in 30 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are critical for various Department of Defense and other federal health service customers, including the Bureau of Prisons and the Department of Veterans Affairs. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, and it is expected to be fully competitive and unrestricted. Interested parties should prepare for the solicitation, projected for November 2024, and can direct inquiries to Nancy Fernandez at nancy.fernandez@dla.mil or by phone at 215-737-4955.
    Pantoprazole DR Tablets
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE Pantoprazole DR Tablets: The Defense Logistics Agency is planning to issue a national requirements contract for Pantoprazole DR Tablets. These tablets, available in 20MG and 40MG strengths, will be provided in 90 and 1000 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The tablets will be purchased by the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the solicitation. Interested parties can find more information on the DLA Bid Board System and Beta Sam.Gov websites. The solicitation is projected to be issued in September 2021.
    Dimethyl Fumarate DR Presolicitation
    Active
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    Azithromycin Suspension Solicitation
    Active
    Dept Of Defense
    The Defense Logistics Agency (DLA) is soliciting proposals for the procurement of Azithromycin Suspension, as outlined in Solicitation No. SPE2D2-25-R-0001. This Request for Proposal (RFP) seeks various formulations of Azithromycin, emphasizing compliance with federal regulations, including the Federal Acquisition Regulation (FAR) and Defense Federal Acquisition Regulation Supplement (DFARS), to ensure the integrity and quality of pharmaceutical supplies. The procurement is critical for maintaining a reliable supply of essential drugs, promoting fair competition among vendors, and adhering to legal provisions regarding production and subcontracting. Interested vendors must submit their offers electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS) between October 29 and December 2, 2024. For further inquiries, contact Kahaun Vicks at Kahaun.Vicks@dla.mil or Jason C. Wray at Jason.Wray@dla.mil.
    Norgestimate/Ethinyl Estradiol Tablets
    Active
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a presolicitation for a national requirements contract for Norgestimate/Ethinyl Estradiol Tablets. The procurement will include various formulations of these oral tablets, specifically Norgestimate Ethinyl Estradiol Triphasic Low Dose Oral Tablets and Ethinyl Estradiol/Norgestimate tablets, packaged in 3x28 count packs. This contract is crucial for establishing a national supply source for the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons, ensuring a reliable provision of these essential pharmaceuticals. Interested parties should prepare for the solicitation, projected for November 2024, and may contact Kyle Lewicki at (215) 737-3696 or kyle.lewicki@dla.mil for further inquiries.
    Rabeprazole Sodium Delayed Release Tablets
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rabeprazole Sodium Delayed Release Tablets. The tablets will be used for medical purposes and will be available in 30, 90, and 500 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source to provide the tablets for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. Interested parties should contact Phyllis Daraio for more information. The projected solicitation date is February 2020.
    Famotidine
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Famotidine, a drug used to treat ulcers and gastroesophageal reflux disease (GERD). The contract will include Famotidine 20 MG tablets in various bottle sizes and Famotidine 40 MG tablets in different bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. The contract aims to establish a national supply source to provide the items for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The annual usage estimates will be provided in the solicitation. The solicitation is expected to be posted on the DLA Bid Board System (DIBBS) and SAM.gov. For any questions or comments, interested parties should contact Kristen Baraniewicz. The projected solicitation date is August 2022, but DLA reserves the right to issue the solicitation before or after that date.
    Metformin HCL
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is planning to issue a national requirements contract for Metformin HCL ER. The contract will establish a national supply source to provide Metformin HCL ER Tablets in various quantities and bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The items will be purchased by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The solicitation will be posted on DLA Bid Board System (DIBBS) and Sam.gov. Interested parties should contact Christopher Newman for any questions/comments. The projected solicitation date is August 2021.